Originally published by our sister publication, Pain Medicine News
The FDA approved atogepant (Qulipta, AbbVie) for the preventive treatment of episodic migraine in adults. Atogepant is the first oral calcitonin gene–related peptide (CGRP) receptor antagonist (gepant) specifically developed for only the preventive treatment of migraine, and not for acute attack treatment.